A relatively high rate of CEACAM6-positive reactivity has been demonstrated in the sera of patients with lung cancer, hepatocellular carcinoma, pancreatic cancer, breast cancer, and colorectal cancer [10]. The gene discussed is CEACAM6; the disease is breast carcinoma.